Printer Friendly

ALKERMES RECEIVES PATENT ON RMP TECHNOLOGY

 ALKERMES RECEIVES PATENT ON RMP TECHNOLOGY
 CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Alkermes, Inc.


(NASDAQ: ALKS) today announced that it has received U.S. patent 5,112,596 on its Receptor-Mediated Permeabilizer (RMP) technology. The claims in this patent include the use of a family of compounds to increase the permeability of the blood-brain barrier when given intravenously. Additional patent applications directed to specific chemical compositions and other aspects of the RMP technology are pending.
 Alkermes is developing RMPs to be used in conjunction with therapeutic compounds for the treatment of infectious diseases of the central nervous system and brain tumor. RMP-7, the lead compound from the RMP family, is currently in phase I clinical trials to evaluate its safety and tolerability in normal volunteers. The company has completed the original protocol for its first phase I study. In this study, no dose limiting adverse experiences were observed at any of the 11 RMP-7 dose levels tested. Trials of RMP-7 in combination with a therapeutic agent in a patient population are expected to begin in late 1992.
 In April 1992, the company announced the closing of a $46 million research and development limited partnership, Alkermes Clinical Partners, L.P., formed to fund further clinical development of RMPs in several indications. The patent has been licensed to the partnership.
 "This first patent relating to our RMP technology is an important milestone for Alkermes," said Richard F. Pops, president and chief executive officer of Alkermes. "The broad coverage it provides will be of increasing importance as we continue the clinical development of RMP-7."
 Alkermes is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of diseases and disorders of the central nervous system.
 -0- 5/14/92
 /CONTACT: Michael J. Landine, chief financial officer of Alkermes, 617-494-0171, or Thomas A. Pearson of Pearson Communications, 215-644-4420, for Alkermes/
 (ALKS) CO: Alkermes, Inc. ST: Massachusetts IN: MTC SU: ERN


TM -- NE007 -- 0276 05/14/92 13:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 14, 1992
Words:336
Previous Article:ADVANCED MEDICAL REPORTS FIRST QUARTER RESULTS
Next Article:ONCOGENE SCIENCE REPORTS SECOND-QUARTER RESULTS
Topics:


Related Articles
ALKERMES AND CORTEX TO COLLABORATE ON STROKE TREATMENT
ALKERMES AND CORTEX ANNOUNCE CALPAIN INHIBITOR DEAL ALKERMES AND CORTEX SETTLE LITIGATION
Targeted Genetics Corporation Announces Strategic Alliance.
Lilly and Alkermes Sign Agreement to Develop Pulmonary Form of Human Growth Hormone.
Amylin Pharmaceuticals and Alkermes Sign Agreement For Development Of Long-Acting Formulation of AC2993 (Synthetic Exendin-4).
MedImmune and Alkermes Sign Agreement to Develop Pulmonary Delivery System For Monoclonal Antibody Against Respiratory Syncytial Virus.
Amylin Pharmaceuticals and Alkermes Demonstrate Extended Release in Initial Phase 1 Study of Long-Acting Formulations of AC2993 (Synthetic Exendin-4).
Bioject and Alkermes Sign License and Development Agreement.
Alkermes Announces Webcast of Presentation at MassOpps Investor Conference.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters